LAB (Standard BioTools) FCF Margin % : -37.33% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Standard BioTools's Free Cash Flow for the three months ended in Dec. 2024 was $-17.4 Mil. Standard BioTools's Revenue for the three months ended in Dec. 2024 was $46.7 Mil. Therefore, Standard BioTools's FCF Margin % for the quarter that ended in Dec. 2024 was -37.33%.

As of today, Standard BioTools's current FCF Yield % is -33.66%.

The historical rank and industry rank for Standard BioTools's FCF Margin % or its related term are showing as below:

LAB' s FCF Margin % Range Over the Past 10 Years
Min: -95.15 Med: -40.94 Max: -20.37
Current: -87.03

During the past 13 years, the highest FCF Margin % of Standard BioTools was -20.37%. The lowest was -95.15%. And the median was -40.94%.

LAB's FCF Margin % is ranked worse than
77.66% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: -3.96 vs LAB: -87.03

Standard BioTools FCF Margin % Historical Data

The historical data trend for Standard BioTools's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools FCF Margin % Chart

Standard BioTools Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-20.37

-43.90

-95.15

-43.37

-87.03

Standard BioTools Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-50.16	-138.90	-110.17	-66.99	-37.33

Competitive Comparison of Standard BioTools's FCF Margin %

For the Medical Devices subindustry, Standard BioTools's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Standard BioTools's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Standard BioTools's FCF Margin % falls into.

Save Embed

Standard BioTools FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Standard BioTools's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-151.809	/	174.432
	=	-87.03 %

Standard BioTools's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-17.441	/	46.718
	=	-37.33 %

Standard BioTools FCF Margin % Related Terms

Thank you for viewing the detailed overview of Standard BioTools's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Standard BioTools Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Standard BioTools Inc (NAS:LAB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FLB:Germany

Address

2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080

Website

https://www.standardbio.com

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Executives

Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black	officer: SVP & Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Fo1-msv, Lp	director	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p.	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis	officer: SVP Chief Commercial Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim	officer: Chief Operating Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm	director, officer: President & CEO	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110